Management of stage III non–small-cell lung cancer: ASCO guideline
ME Daly, N Singh, N Ismaila, MB Antonoff… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
Radiation oncology in the era of precision medicine
Technological advances and clinical research over the past few decades have given
radiation oncologists the capability to personalize treatments for accurate delivery of …
radiation oncologists the capability to personalize treatments for accurate delivery of …
Lung cancer: Biology and treatment options
H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
Management of non-small-cell lung cancer: recent developments
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer
A Aupérin, C Le Péchoux, E Rolland… - Journal of clinical …, 2010 - ascopubs.org
Purpose The previous individual patient data meta-analyses of chemotherapy in locally
advanced non–small-cell lung cancer (NSCLC) showed that adding sequential or …
advanced non–small-cell lung cancer (NSCLC) showed that adding sequential or …
Non-small-cell lung cancer
In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …
Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice …
Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …
population with disease presentation ranging from apparently resectable tumors with occult …
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
G Goeckenjan, H Sitter, M Thomas, D Branscheid… - …, 2010 - thieme-connect.com
Qualitätsindikatoren wurden durch Sens et al. wie folgt definiert:„Ein Indikator ist ein
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …
[HTML][HTML] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
L Crino, W Weder, J Van Meerbeeck, E Felip… - Annals of oncology, 2010 - Elsevier
Improving survival in lung cancer is a major challenge for modern oncology considering that
5-year survival remains< 15%, across all stages of disease and with< 7% of patients alive 10 …
5-year survival remains< 15%, across all stages of disease and with< 7% of patients alive 10 …
Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage …
JS Ahn, YC Ahn, JH Kim, CG Lee, EK Cho… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and
cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally …
cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally …